BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium chloride) after…
Central Nervous System
-
-
Coya Therapeutics hopes for ALS Treg approval on Phase II trial
Coya Therapeutics is hoping to gain approval of its amyotrophic lateral sclerosis (ALS) disease-modifying therapy (DMT) based on its Phase…
-
Vesper Bio’s FTD candidate shows progranulin increase in Phase Ib/IIa trial
Vesper Bio’s frontotemporal dementia (FTD) drug has increased progranulin levels in a Phase Ib/IIa trial, showing its potential in slowing…
-
Multiple sclerosis: three trials to watch
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to…
-
BridgeBio’s stock up as muscular dystrophy therapy meets Phase III endpoints
BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its endpoints in…
-
FDA lifts clinical hold on Neurizon’s ALS drug
The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
-
Vertanical’s cannabis-based pain relief beats opioids
Vertanical’s cannabis-based pain reliever, VER-01, has shown superiority over opioids in a Phase III trial. In the ELEVATE study (NCT05610813),…
-
Trials to watch: Three major catalysts in Alzheimer’s disease
Eli Lilly and Biogen/Eisai continue to have a hold on the Alzheimer’s disease market after the approvals of their therapies…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market
On 26 August, Regeneron announced exciting results from Phase III clinical trial NIMBLE (NCT05070858) evaluating the efficacy and safety of…
